Washington – Johnson & Johnson will buy Swiss drugmaker Actelion in a $30 billion deal that both secures promising research and bolsters the product portfolio controlled by the U.S. health care giant.
Much of Actelion’s research operation will be spun off into a separate company in which J&J will own a minority stake. The U.S. conglomerate will then buy Actelion’s seven drugs that are currently on the market and two potential treatments in late-stage testing.
J&J will own 16 percent of the new, stand-alone business.
